- About Us
- Clinical Trials
Available Clinical Trials
- Resources
- Contact Us
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
BN007 is closed to accrual, effective March 29, 2023.